Bibliography
- Zhang J, Gold KA, Kim E. Sorafenib in non-small-cell lung cancer. Expert Opin Biol Ther 2012;21(8): PMID 22725255
- Scagliotti G, Novello S, von Pawel J, Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(11):1835-42
- Gatzemeier U, Eisen T, Santoro A, Sorafenib (S) 1 Gemcitabine/Cisplatin (GC) vs GC alone in the first-line treatment of advanced Non–Small Cell Lung Cancer (NSCLC): phase III nsclc research experience utilizing sorafenib (NEXUS) trial. Ann Oncol 2010;21(8):viii7
- Lind JS, Dingemans AM, Groen HJ, A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16(11):3078-87
- Gridelli C, Morgillo F, Favaretto A, Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Ann Oncol 2011;22(7):1528-34
- Spigel DR, Burris HA III, Greco FA, Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 29(18):2582-9
- Blumenschein GR Jr, Gatzemeier U, Fossella F, Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27(26):4274-80
- Schiller JH, Lee JW, Hanna NH, A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. ASCO Meeting Abstr 2008;26(15 Suppl):8014
- Reck M, Kaiser R, Eschbach C, A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011;22(6):1374-81
- Huang D, Ding Y, Zhou M, Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010;70(3):1063-71
- Xu CF, Bing NX, Ball HA, Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011;29(18):2557-64
- Zurita AJ, Jonasch E, Wang X, A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23(1):46-52
- Dowlati A, Gray R, Sandler AB, Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab–an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14(5):1407-12
- Hanrahan EO, Ryan AJ, Mann H, Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009;15(10):3600-9
- Herbst RS, Blumenschein GR, Kim ES, Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. ASCO Meeting Abstr 2010;28(15 Suppl):7609